| ²é¿´: 272 | »Ø¸´: 3 | ||||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | ||||
[½»Á÷]
¡¾ÇóÖú¡¿ÈçºÎ·Òë¸üÌùÇУ¬Ð»Ð»¸÷λ
|
||||
|
However, for these other sources adoption of a concentration limit and a validated method in the specification is only necessary in the very exceptional cases where these residues are known to be insufficiently limited by GMP, GDP or any other relevant provision. Pharmaceutical companies are not supposed to perform extensive tests on metal residue findings of unknown sources to comply with this guideline. They may rely on general information from trustworthy suppliers. |
» ²ÂÄãϲ»¶
ÖÐɽ´óѧ-µÚÆßÒ½Ôº-ÕпÆÑÐÖúÀí1Ãû£¨»ùÒòÉè¼ÆºÍ¿Ë¡¡¢RNAºÏ³É£©
ÒѾÓÐ1È˻ظ´
°ÍÀèÈø¿ËÀ×´óѧÓë¹ú¼ÒÁôѧ»ù½ðίºÏ×÷²©Ê¿Ñо¿ÉúÏîÄ¿-Ö¬ÖÊÄÉÃ×Ò©Îï/ÉúÎï²ÄÁÏ/¶à·ÓµÝËÍ
ÒѾÓÐ10È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ104È˻ظ´
½õÖÝÒ½¿Æ´óѧҩÓÃÉúÎï²ÄÁÏ£¨×¨Òµ´úÂë1007Z1£©ÕÐÊÕµ÷¼Á¿¼Éú
ÒѾÓÐ0È˻ظ´
½õÖÝÒ½¿Æ´óѧҩÓÃÉúÎï²ÄÁÏ£¨×¨Òµ´úÂë1007Z1£©ÕÐÊÕµ÷¼Á¿¼Éú
ÒѾÓÐ2È˻ظ´
26É격×Ô¼ö
ÒѾÓÐ12È˻ظ´
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
Çó´óÀÐÊÕÁô
ÒѾÓÐ0È˻ظ´
Õâ¸ö×Ô·¢¼ÓÑõ·´Ó¦µÄ»úÀíÊÇʲô£¿
ÒѾÓÐ7È˻ظ´
2Â¥2009-08-26 07:59:41
´ÓÍ·¿ªÊ¼
ÈÙÓþ°æÖ÷ (ÎÄ̳¾«Ó¢)
gost rider~
-

ר¼Ò¾Ñé: +1 - DRDEPI: 2
- Ó¦Öú: 66 (³õÖÐÉú)
- ¹ó±ö: 3.308
- ½ð±Ò: 350018
- É¢½ð: 60688
- ºì»¨: 595
- ɳ·¢: 1386
- Ìû×Ó: 43542
- ÔÚÏß: 8442Сʱ
- ³æºÅ: 812211
- ×¢²á: 2009-07-20
- רҵ: Ò©¼Áѧ
- ¹ÜϽ: ÐÂÒ©Ñз¢
¡ï ¡ï ¡ï ¡ï ¡ï
Çà²Ø¸ßÔ(½ð±Ò+5,VIP+0):лл 8-27 08:19
Çà²Ø¸ßÔ(½ð±Ò+5,VIP+0):лл 8-27 08:19
|
È»¶ø£¬¶ÔÓÚÕâ¸ö¹æ·¶ÀïÃæ²ÉÄɵĹØÓÚŨ¶ÈÏ޶ȺÍÑéÖ¤·½·¨µÄÕâЩÆäËûÎļþ£¬Ö»ÓÐÔÚ²»Âú×ãGMP,GDP»òÕ߯äËûÏà¹Ø¹æ¶¨µÄÌØÊâÇé¿öϲÅÊDZØÐëµÄ¡£ÖÆÒ©ÆóҵûÓбØÒªÎªÒÀ´ÓÕâ¸öÖ¸µ¼Îļþ¶ø¶Ô²»Ã÷À´Ô´µÄ½ðÊô²ÐÁô×ö¶îÍâµÄ¼ì²é¡£ËûÃÇ¿ÉÒÔÒÀ¾Ý¿É¿¿¹©Ó¦É̵Ļù±¾ÐÅÏ¢¡£ Å×שÒýÓñ£¬Ï£Íû»¹Óиü¶à¸üºÃµÄ·Òë³öÀ´¡£ lzÌṩ½ð±ÒÓеãÉÙŶ~~~ ![]() ![]() |

3Â¥2009-08-26 10:59:07
liushilei1111
ľ³æ (ÖøÃûдÊÖ)
ÕæÏëתÐÐ
- Ó¦Öú: 11 (СѧÉú)
- ½ð±Ò: 4604.4
- Ìû×Ó: 1737
- ÔÚÏß: 68.6Сʱ
- ³æºÅ: 411910
- ×¢²á: 2007-06-24
- ÐÔ±ð: GG
- רҵ: Ò©¼Áѧ

4Â¥2009-09-02 14:40:53









»Ø¸´´ËÂ¥
